Piekos Brian 4
4 · KalVista Pharmaceuticals, Inc. · Filed Sep 11, 2024
Insider Transaction Report
Form 4
Piekos Brian
Chief Financial Officer
Transactions
- Award
Employee Stock Option (right to buy)
2024-09-09+100,000→ 100,000 totalExercise: $11.87→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.